Current Research & Innovations

Kidney

• A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation. — (Mark Hardy, MD)
• A Phase IV, Randomized, Open-Label, Comparative, Multicenter Study to Asses the ... — (Mark Hardy, MD)
• An Open-Label, Concentration-Controlled, Randomized, 12 Month study of prograf+R... — (Mark Hardy, MD)
• Antithymocyte globulin induction in prevention of allograft ischemia/reperfusion injury in renal transplant recipients. — (Mark Hardy, MD)
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial — (Mark Hardy, MD)
• Facilitated Access program to provide Everolimus for maintenance for patients co... — (Mark Hardy, MD)
• MORE Registry -- Mycophenolic acid Observational REnal Transplant Program (Enrollment is closed for this study.) —The MORE Registry is a Phase IV, Non-Interventional, Multi-center, Open-Label, Prospective, Observational Study of the Safety, Effectiveness, Tolerability and Compliance of Immunosuppressive Regimens. The main objective is to describe center practices and to compare the short and long term outcomes, including tolerability, safety, effectiveness, and patient compliance of current and newly emerging immunosuppressive regimens used in the management of de novo renal transplant patients in routine clinical practice. The regimens will include MPA (mycophenolic acid) therapy constituting either myfortic® (ECMPS) or CellCept® (MMF). (Lloyd Ratner, MD)
• Pharmacokinetic Evaluation of Plasmapheresis in Cross Match Positive or ABO Incompatible Kidney Allograft Recipientst (This trial not yet enrolling; please call 212-305-2813 for more information.) —The primary endpoint will be the determination of immune globulin, Tacrolimus, Mycophenolate Mofetil and Daclizumab levels before, during and after plasmapheresis treatments. Secondary endpoints will include changes in antibody titer, PRA reduction and cross-matching. (Lloyd Ratner, MD)
• Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis — (Roman Nowygrod, MD)
• Randomized, Double-Blind, Placebo-Controlled, Dose response study of the safety ... — (Mark Hardy, MD)
• Renal Cell Cancer Treatment: Evaluating TroVax in Conjunction with Interleukin-2 (IL-2) —A preliminary study of the safety, immunogenicity, and clinical efficacy of TroVax given in conjunction with Interleukin-2 (IL-2) in the treatment of stage IV renal cell cancer. (Howard Kaufman, MD)